CI vs RCUS · P/E 2.4, rev $274.90B vs rev $258.0M
Cigna Corp (CI) versus Arcus Biosciences Inc (RCUS) — a side-by-side from cached financials, not a winner call.
Cigna Corp (CI) is a healthcare plans company listed on US.
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on US.
Latest reported CI revenue for 2025-12-31 was $274.90B. Net income was $5.96B. Revenue was up 11.2% from 2024-12-31 to 2025-12-31. CI currently screens at market cap $71.62B and trailing P/E 2.4.
Latest reported RCUS revenue for 2024-12-31 was $258.0M. Net income was -$283.0M. Revenue was up 120.5% from 2023-12-31 to 2024-12-31. RCUS currently screens at market cap $885.2M.
CI currently screens at market cap $71.62B and trailing P/E 2.4. RCUS currently screens at market cap $885.2M.
Not investment advice. Open the CI and RCUS stock pages for the full models.
Not investment advice.